ArticleBMC infectious diseases2026
Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionSalmonella enterica serotype Kentucky (S. Kentucky) is a globally distributed food-borne zoonotic pathogen. It is increasingly associated with multi-drug resistance (MDR), notably to ciprofloxacin, a trend largely attributed to antibiotic overuse in humans and livestock. CASE PRESENTATION: An acute erythroid leukemia (AML-M6) man was found to be infected with carbapenem-resistant (CR) Salmonella enterica after chemotherapy. Salmonella serum agglutination test showed that the strain belonged to S. Kentucky. Antimicrobial susceptibility test showed that this strain is an MDR strain (resistant to carbapenems, ciprofloxacin, third-generation cephalosporins). Carbapenemase production was assessed via a colloidal gold immunochromatography assay and indicated expression of an NDM enzyme. Whole genome sequencing (WGS) revealed that this strain carried blaNDM-5, blaCTXM-55, and blaTEM-1 genes. Based on the identification of an NDM carbapenemase, in vitro synergy testing was performed, which demonstrated a synergistic effect between aztreonam and ceftazidime-avibactam. The patient was successfully treated with this combination regimen and recovered.
conclusionsThis report describes an unusual infection caused by an NDM-5-producing S. Kentucky in an immunocompromised host. It underscores the necessity of employing combined phenotypic, immunologic, and molecular diagnostics to rapidly elucidate resistance mechanisms in such complex cases. Guided by this comprehensive analysis, the combination of aztreonam and ceftazidime-avibactam proved to be an effective, mechanism-based therapeutic strategy, highlighting its value in managing challenging infections in patients with hematological malignancies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.